Co-Authors
This is a "connection" page, showing publications co-authored by LUHUA WANG and ROBERT ORLOWSKI.
Connection Strength
1.687
-
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48.
Score: 0.222
-
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41.
Score: 0.125
-
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8.
Score: 0.120
-
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83.
Score: 0.118
-
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56.
Score: 0.116
-
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70.
Score: 0.112
-
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood. 2011 Oct 13; 118(15):4140-9.
Score: 0.104
-
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011 Mar; 152(5):579-92.
Score: 0.100
-
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011 Apr 01; 286(13):11009-20.
Score: 0.099
-
Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011 Mar 17; 30(11):1329-40.
Score: 0.098
-
High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant. 2015 May; 50(5):668-72.
Score: 0.033
-
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
Score: 0.032
-
The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014 Jul 29; 111(3):628-36.
Score: 0.032
-
Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. 2014 Aug; 49(8):1036-41.
Score: 0.032
-
Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014 Apr 03; 123(14):2204-8.
Score: 0.031
-
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
Score: 0.030
-
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6.
Score: 0.029
-
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 04; 120(14):2817-25.
Score: 0.028
-
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70.
Score: 0.027
-
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6.
Score: 0.027
-
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.
Score: 0.026
-
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.
Score: 0.026
-
Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22.
Score: 0.026
-
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.
Score: 0.026
-
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther. 2011 Jan; 10(1):148-58.
Score: 0.025
-
Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52.
Score: 0.024
-
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2.
Score: 0.020